Doing some research...
Statement
Assets, liabilities and equity aligned across the annual filing history, in USD millions.
Assets
+7.4% YoYReported for FY 2025
Liabilities
+0.6% YoYReported for FY 2025
Equity
+14.3% YoYReported for FY 2025
Equity mix
+3.2 ppEquity share of the capital base
Table view
Balance sheet, reported dollar amounts — FY 2025
Every figure is the balance as filed. Each filing badge opens the SEC index page for that fiscal year.
Structure
Assets plotted against the liabilities and equity stack, so you can see how the balance sheet is financed.
Liabilities and equity stack to the capital base; assets are the dashed reference line.
Composition
The same split read as a share of total capital rather than in absolute dollars.
Percentages are measured against total capital for each fiscal year.
Trend
How assets, liabilities and equity have moved across the annual balance sheet window.
Switching between bar and line keeps the selected year order.
Commentary
This explanation uses an earlier data snapshot or evidence version. Compare its generation date with the current filing figures.
Earlier AI snapshot · Generated Jun 10, 2026. The filing-backed figures above are the current source of truth.
Agilent Technologies’ balance sheet shows a generally stable-to-improving financial position over the five-year period, with total assets rising from about $10.7 billion in 2021 to $12.7 billion in 2025. After a slight dip in 2022, assets increased steadily in 2023, 2024, and 2025, suggesting continued investment in the business and/or solid organic growth. Total liabilities were broadly flat in the $5.2–$5.9 billion range, with a modest increase in 2023 and then relatively stable levels through 2025. This indicates that asset growth was not driven by a large increase in leverage. Stockholders’ equity is the most notable part of the trend, improving from roughly $5.4 billion in 2021 to $6.7 billion in 2025, despite a sharp anomaly in 2023 where equity is reported as negative. That 2023 figure appears unusual relative to the surrounding years and may reflect a one-time accounting adjustment, acquisition-related charge, or data issue rather than a sustained deterioration in net worth. Overall, by 2024–2025 the company appears to have restored and strengthened its equity base, which is generally positive for a life sciences and analytical instruments company where balance-sheet resilience supports R&D, acquisitions, and cyclical demand management.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.